Literature DB >> 8514744

Nephrogenic diabetes insipidus. A V2 vasopressin receptor unable to stimulate adenylyl cyclase.

W Rosenthal1, A Antaramian, S Gilbert, M Birnbaumer.   

Abstract

The coding region of the human vasopressin type 2 receptor gene bears mutations in the individuals affected with congenital nephrogenic diabetes insipidus, a disease characterized by the inability of the kidney to concentrate urine in response to vasopressin. Although it is assumed that the mutations result in loss of receptor function, proof of this hypothesis is lacking. We introduced one of these naturally occurring point mutations leading to a single amino acid change (Arg137-->His) into wild type cDNA. The mutant protein was expressed, and the functional properties of the receptor were examined. The mutant receptor exhibited an unaltered binding affinity for vasopressin compared to the wild type but failed to stimulate the Gs/adenylyl cyclase system. These data provide biochemical proof that the mutant receptor is the cause of the disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8514744

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

Review 1.  Genetic variations in human G protein-coupled receptors: implications for drug therapy.

Authors:  W Sadee; E Hoeg; J Lucas; D Wang
Journal:  AAPS PharmSci       Date:  2001

2.  Common structural requirements for heptahelical domain function in class A and class C G protein-coupled receptors.

Authors:  Virginie Binet; Béatrice Duthey; Jennifer Lecaillon; Claire Vol; Julie Quoyer; Gilles Labesse; Jean-Philippe Pin; Laurent Prézeau
Journal:  J Biol Chem       Date:  2007-02-19       Impact factor: 5.157

3.  Characterization of intracellular signaling mediated by human somatostatin receptor 5: role of the DRY motif and the third intracellular loop.

Authors:  Erika Peverelli; Andrea G Lania; Giovanna Mantovani; Paolo Beck-Peccoz; Anna Spada
Journal:  Endocrinology       Date:  2009-04-02       Impact factor: 4.736

4.  Molecular Architecture of G Protein-Coupled Receptors.

Authors:  A Michiel van Rhee; Kenneth A Jacobson
Journal:  Drug Dev Res       Date:  1996-01-01       Impact factor: 4.360

5.  Role of the intracellular domains of the human FSH receptor in G(alphaS) protein coupling and receptor expression.

Authors:  Alfredo Ulloa-Aguirre; Aída Uribe; Teresa Zariñán; Ismael Bustos-Jaimes; Marco A Pérez-Solis; James A Dias
Journal:  Mol Cell Endocrinol       Date:  2006-10-12       Impact factor: 4.102

6.  The effect of aspartate-lysine-isoleucine and aspartate-arginine-tyrosine mutations on the expression and activity of vasopressin V2 receptor gene.

Authors:  Hossein Najafzadeh; Leila Safaeian; Hamid Mirmohammad Sadeghi; Mohammad Rabbani; Abbas Jafarian
Journal:  Iran Biomed J       Date:  2010 Jan-Apr

7.  Agonist-independent interactions between beta-arrestins and mutant vasopressin type II receptors associated with nephrogenic syndrome of inappropriate antidiuresis.

Authors:  Martina Kocan; Heng B See; Natália G Sampaio; Karin A Eidne; Brian J Feldman; Kevin D G Pfleger
Journal:  Mol Endocrinol       Date:  2009-01-29

8.  Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus.

Authors:  D G Bichet; M Birnbaumer; M Lonergan; M F Arthus; W Rosenthal; P Goodyer; H Nivet; S Benoit; P Giampietro; S Simonetti
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

9.  Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression.

Authors:  D W McGraw; S L Forbes; L A Kramer; S B Liggett
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

10.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

Authors:  C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.